Cancer Network
April 07, 2025
Rajat Thawani, MBBS, leads a panel on considerations for tyrosine kinase inhibitor selection and sequencing in the first and second lines of treatment for patients with stage IIIB to IV ALK-positive non-small cell lung cancer at the CancerNetwork “Meeting of the Minds” program. Thawani says, “Broadly the metabolic and neuropsychiatric [adverse] effects, both of them [can be] challenging in lorlatinib, but it seems like with holds and temporary discontinuations, you can get it under control”